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1. Introduction    
Many researchers have reported that vasodilators, such as angiotensin-converting enzyme 
inhibitors (The CONSENSUS Trial Study Group, 1987), angiotensin receptor blockers (Cohn 
et al., 1999), and beta-blockers (CIBIS Investigators et al., 1994), improve prognosis in 
patients with chronic heart failure (CHF). Furthermore, new technologies to treat CHF, such 
as cardiac rehabilitation, cardiac resynchronization therapy, left ventricular assist devices, 
and left ventricular reconstruction surgery, have been developed over the past decade. 
Despite advances in therapy for heart failure, improving clinical outcomes of patients with 
acute decompensation of CHF remains a challenge for physicians. Re-hospitalization within 
60—90 days occurs in approximately 30% of patients with acute decompensation of CHF 
(Mann, 2008). 
In 1989, Tei et al. developed a form of thermal therapy for heart failure that uses a variation 
of the traditional dry sauna with temperature maintained at 60°C (Tei et al., 1994; Tei et al., 
1995). This new form of thermal treatment is defined as warming the entire body in a 
uniformly heated chamber for 15 min at a temperature that relaxes both the mind and body. 
After the core temperature has increased by 1.0–1.2°C, the patient rests outside the sauna for 
a further 30 min to maintain the soothing effect, and fluids corresponding to perspiration 
loss are supplied to protect against dehydration at the end of therapy (Tei, 2007). 
Tei et al. have previously reported that the repeated use of a dry 60 ◦C sauna by CHF 
patients improves hemodynamics (Tei et al., 1995), ameliorates symptoms (Tei & Tanaka, 
1996), suppresses ventricular arrhythmias (Kihara et al., 2004), and improves vascular 
function (Kihara et al., 2002). Recently, in a prospective multicenter case-control study, 2 
weeks of dry sauna therapy was shown to improve clinical symptoms and cardiac function 
in CHF patients (Miyata et al., 2008). Repeated sauna therapy also improved survival in TO-
2 cardiomyopathic hamsters with heart failure (Ikeda et al., 2002). A recent retrospective 
follow-up study (Kihara et al., 2009) has shown that sauna therapy decreased cardiac death 
and re-hospitalization in patients with CHF over a 60-month follow-up period. 
A large number of end-stage CHF patients in Japan have been implanted with a left 
ventricular assist device (LVAD) because of prolonged waiting periods for heart transplants 
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(Osada et al., 2005). Although we wished to apply sauna thermal therapy to patients with 
LVAD, we do not have an appropriate sauna facility. Instead, we attempted to apply lower 
limb thermal therapy to the patients with LVAD awaiting a heart transplant. This paper 
describes for the first time the safety and effectiveness of this preliminary trial of lower limb 
thermal therapy for patients with end-stage heart failure. 
2. Methods 
2.1 Patients and study design  
The study subjects included 5 consecutive  end-stage CHF patients who were listed on a 
waiting list for heart transplants in the National Cardiovascular Center, Osaka, Japan. All 
patients had dilated cardiomyopathy refractory to maximal medical therapy, including  
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, 
diuretics, and digitalis. Regardless of intensive care with intravenous inotropic agents, heart 
failure rapidly progressed to cardiogenic shock in the patients. They were fitted with 
extracorporeal LVAD (VCT-50, Toyobo Ltd., Osaka, Japan) to stabilize their hemodynamics. 
None of the patients was implanted with a defibrillator device.  
 
 
Fig. 1. Typical settings for lower limb thermal therapy for a patient with left ventricular 
assist device. 
The patients’ general condition stabilized thereafter and the status of heart failure at the 
time of study was New York Heart Association (NYHA) class II. Although this status 
remained stable for at least 6 months, the patients’ cardiac function did not sufficiently 
recover to allow discontinuation of LVAD support. All patients provided written informed 
consent to enter into the clinical trial for lower limb thermal therapy. The Ethics Committee 
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at the National Cardiovascular Center approved the protocol, and the study was conducted 
in accordance with the Declaration of Helsinki. The study consisted of clinical examinations 
before and after a 2-week treatment consisting of daily thermal therapy using a steam bath 
at 42 ◦C applied to the lower legs and feet (Fig. 1). After 15 min of therapy at 42 ◦C, the 
patient remained seated in the steam bath with the lower legs and feet wrapped with a 
blanket for a further 30 min. The procedure was accompanied by electrocardiographic 
monitoring. The patient remained on the same medications with same dose throughout the 
study period. 
A typical example of lower limb thermal therapy is illustrated in Fig.1.  The study protocol 
for the 2-week treatment was illustrated in Fig.2. 
 
 
Fig. 2. Illustrative presentation of the study design for lower limb thermal therapy. 
2.2 Measurements 
Systolic and diastolic blood pressure (BP), heart rate, body weight, and surface and deep 
body temperature (axillary and sublingual) were measured daily throughout the study. 
Chest X-ray, ambulatory electrocardiogram, echocardiogram, and peripheral arterial 
tonometry were recorded and blood was sampled prior to and 2 weeks after the treatment. 
Blood samples were used for measurement of plasma BNP, serum NT-proBNP, plasma 
nitrates and nitrites, plasma hydroperoxides and HClO expense test. 
Medical interviews were done every morning to evaluate the clinical status of CHF by NYHA 
functional class, and to estimate the patients’ daily life activities using a Specific Activity Scale 
(SAS). We used the Specific Activity Scale as a measure of QOL, in which self perceived 
exercise tolerance is expressed by an energy cost spent in the maximal physical activity that 
the patient can perform (Sasayama et al., 1992). The Specific Activity Scale allows expression of 
the extent of submaximal physical activity. Sasayama et al. actually measured the metabolic 
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costs of various types of physical activity by hooking subjects up to a mask to measure oxygen 
consumption and the volume of carbon dioxide exhaled. They then prepared questionnaires 
about specific physical activities that a patient would perform either customarily or 
sporadically in daily life and each patient was asked to specify whether he/she could perform 
each type of activity without symptomatic limitations. Summarizing the questionnaire data, a 
given number of metabolic costs (Specific Activity Scale) were derived for each patient with 
regard to their self-perceived exercise tolerance. As a clear linear correlation was observed 
between Specific Activity Scale and peak oxygen consumption, the Specific Activity Scale was 
considered to provide a reliable prediction of exercise capacity (Sasayama et al., 1992) 
Prior to and 2 weeks after the treatment, the cardiothoracic ratio (CTR) was measured by 
chest radiography and the count of premature ventricular beats was evaluated daily with an 
ambulatory electrocardiogram. Prior to and 2 weeks after the treatment, two-dimensional 
echocardiography were performed to determine left ventricular systolic (LVDs) and 
diastolic dimension (LVDd), left atrial dimension (LAD), LVEF and degree of mitral 
regurgitation. The left ventricular (LV) end-diastolic and end-systolic volumes were 
determined according to a modification of Simpson’s method. LVEF was calculated as end-
diastolic minus end-systolic volume divided by end-diastolic volume. 
Each patient was instructed to lie quietly and undisturbed for at least 30 min, and then a 
venous blood sample was withdrawn through an indwelling catheter in the forearm. Plasma 
was immediately separated and stored at 70°C until analysis.  
Norepinephrine (NE) concentrations were determined by high performance liquid 
chromatography and electrochemical detection. Plasma brain natriuretic peptide (BNP) was 
determined by the chemiluminescent enzyme immunoassay.  
For nitric oxide (NO) measurement, the blood specimen was placed immediately in an ice 
bath and centrifuged within 30 seconds for 5 minutes at 2000g. The serum fraction was 
diluted 1:1 with nitrite- and nitrate-free distilled water, and 400 mL of the diluted sample 
was centrifuged at 2000g in an ultra-free MC microcentrifuge device (Millipore) to remove 
substances larger than 10 kD. The filtrate was passed through a copper-plated cadmium 
column to reduce nitrate to nitrite and then reacted with Griess reagents consisting of 0.1% 
naphthylethylenediamine dihydrochloride in distilled water and 1% sulfanilamide in 5% 
H3PO4, after which absorbance was measured at 540 nm to provide the total amount of 
plasma NO end products (nitrate plus nitrite). The efficiency of the cadmium column in the 
conversion of nitrate to nitrite was confirmed to be 100% by measuring both nitrate and 
nitrite standards before and after sample measurement (Node et al., 1997).  
Plasma hydroperoxides, which were determined by the Diacron reactive oxygen metabolites 
test, were used as a marker of oxidative stress (Cesarone et al., 1999) while the OXY 
absorbent test was used to measure buffering potential against the oxidant action of 
hypochlorous acid (HClO), which was quantified by HClO neutralization, and represented a 
marker of anti-oxidative potency (Trotti et al., 2001).  
Endothelial function was quantified by the reactive hyperemic (RH) change in digital blood 
flow after arm occlusion using a peripheral fingertip arterial tonometry (PAT) device (Endo-
PAT 2000 system; Itamar-Medical, Caesarea, Israel)( Bonetti et al., 2004;  Hamburg & 
Benjamin, 2009). After 5 min of baseline recording, a BP cuff was inflated to supra-systolic 
pressure in the test arm. After 5 min of occlusion, the cuff was rapidly deflated, with PAT 
tracings recorded. The reactive hyperemic PAT (RH-PAT) response was determined as the 
ratio of PAT amplitude in the test arm to that in the control arm, averaged over  30-s 
intervals after cuff deflation, divided by the average PAT ratio measured for the 140-s 
interval before cuff inflation. RH-PAT ratio was assessed between 60 s and 120 s after 
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occlusion and was the log-transformed value of the post-deflation to baseline pulse 
amplitude in the hyperemic finger normalized to the contralateral finger. 
2.3 Statistical analysis 
All data are expressed as means ±S.D. Value of BNP was log-transformed to remove 
skewness of data distribution. The data prior to and 2 weeks after treatment were compared 
using a paired t-test. A p-value of <0.05 was considered statistically significant. 
3. Results 
3.1 Clinical findings and physical examinations  
Table 1 summarizes the results of clinical findings and physical examinations. During the 
study, none of the patients treated with lower limb thermal therapy showed worsened 
clinical symptoms. The changes in the clinical findings and variables after 2 weeks are 
indicated in Τable 1. Although the NYHA functional class remained similar, activity of daily 
life estimated by SAS system tended to decrease (p=0.058). Systolic and diastolic blood 
pressure and heart rate did not differ between the baseline and 2 weeks after therapy.  No 
significant change was noted in body weight.   
 
 Before After p value 
Sample size 5 5  
Age (years) 35.4±8.8   
NYHA functional class 2.8±0.4 2.6±0.5 0.374 
Activity of Daily Life (METs) 2.66±0.85 3.12±1.11 0.058 
Ventricular Premature Beats (per day) 121.8±70.2 71.6±62.2 0.143 
Body Weight (kg) 53.0±10.1 52.9±10.1 0.355 
Systolic blood pressure (mmHg) 97.4±13.0 99.2±17.0 0.505 
Diastolic blood pressure (mmHg) 55.0±10.4 58.2±9.4 0.216 
Heart Rate (bpm) 80.0±34.8 79.6±29.7 0.914 
Morning Body Temperature (C) 35.9±0.45 36.0±0.39 0.296 
Deep Body Temperature (C) 36.0±0.29 36.8±0.23 0.004 
Cardiothoracic Ratio (%) 53.7±14.8 52.2±14.7 0.082 
Norepinephrine (pg/mL) 974.2±584.8 801.6±482.7 0.041 
log BNP (pg/mL) 2.128±0.516 2.080±0.505 0.035 
Nitrogen oxide (μmol/L) 25.1±6.7 47.6±19.8 0.028 
Hydroperoxides (carr U) 501.4±77.5 430.4±84.2 0.0003 
OXY absorbent test (μmol HClO/mL) 397.6±41.9 461.6±56.4 0.096 
LAD (mm) 42.8±11.2 42.4±10.0 0.731 
LVDd (mm) 54.4±12.0 53.0±13.3 0.184 
LVDs (mm) 43.1±15.4 39.7±15.9 0.014 
LV Ejection Fraction (%) 43.0±19.3 51.1±18.5 0.0007 
Mitral Regurgitation (grade) 2.2±1.1 1.4±0.9 0.016 
RH-PAT ratio 1.39±0.24 2.05±0.30 0.02 
BNP brain natriuretic peptide, LAD left atrial dimension, LVDd left ventricular diastolic 
dimension, LVDs left ventricular systolic dimension, NYHA New York Heart 
Association, RH-PAT reactive hyperemic peripheral arterial tonometry 
Table 1. Summary of changes in parameters before and after the thermal therapy 
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3.2 Chest radiography and echocardiography 
Table 1 also  presents the results of chest radiography and echocardiography. Chest 
radiography showed a non-significant decrease of the CTR after 2 weeks of treatment when 











Fig. 4. Representative illustration of the changes in the tracing of peripheral arterial 
tonometry before and after the therapy 
www.intechopen.com
Initial Experience of Lower Limb Thermal Therapy for Patients  
with an Extracorporeal Left Ventricular Assist Device Awaiting Heart Transplantation   
 
131 
While, echocardiography demonstrated similar dimensions in LAD and LVDd after 
treatment, LVDs and LVEF significantly decreased after the therapy (Table 1). Doppler 
echocardiography demonstrated that the extent of mitral regurgitation decreased after 
treatment  (Table 1, Fig. 3).  
3.3 Plasma levels of norepinephrine, BNP, nitrogen oxide and hydroperoxides, and 
result of OXY adsorbent test 
Table 1 shows the changes in plasma concentration of norepinephrine, BNP, nitrogen oxide 
(nitrate plus nitrite) and hydroperoxides. Plasma concentration of norepinephrine 
significantly decreased after 2 weeks of the therapy. The plasma concentration of BNP 
significantly decreased after 2 weeks of the therapy. Plasma concentration of nitrogen oxide 
䋨nitrate plus nitrite䋩, the stable metabolite of nitric oxide, significantly increased after 2 
weeks of the therapy. Plasma concentration of hydroperoxides, a biomarker that reflects 
oxidative stress, significantly decreased after 2 weeks of the therapy. The OXY absorbent 
test, a marker of anti-oxidative potency, showed a non-significant increase after 2 weeks of 
the therapy.  
3.4 Endothelial function 
The RH-PAT ratio was augmented 2 weeks after the therapy (Table 1, Fig.4).  
4. Discussion 
This is the first report of lower limb thermal therapy being applied to patients implanted 
with LVAD and awaiting heart transplantation. Whole body sauna therapy for CHF is 
widely recognized to result in improved clinical symptoms, cardiac function, quality of life, 
and ventricular arrhythmia, and in decreased levels of abnormally activated neurohumoral 
factors (Tei et al., 1995; Tei & Tanaka, 1996; Tei 2007; Kihara et al., 2002; Kihara et al., 2004). 
However, whole body sauna therapy is impractical for patients with CHF in general 
hospitals that lack specialized sauna facilities, whereas lower limb thermal therapy using a 
steam bath can be applied routinely right in the patients’ rooms.  
Increases in deep body temperature of 1.0—1.2 ◦C during sauna therapy dilate systemic 
arteries and veins, thereby reducing systemic preload and afterload and resulting in 
increased cardiac output (Tei et al., 1995; Tei & Tanaka, 1996; Tei 2007; Kihara et al., 2002; 
Kihara et al., 2004). The sublingual temperature of the patients in the present study was 
increased by about 0.8 ◦C after the therapy. Nevertheless, the benefits seemed to be similar 
to those of sauna therapy. Ikeda et al. found that repeated sauna therapy increases 
endothelial nitric oxide synthase expression and nitric oxide production, and improves 
cardiac function in animal models of heart failure (Ikeda et al., 2001; Ikeda et al., 2005). 
Serum nitrate plus nitrite levels doubled in our patients, when compared with the baseline 
values, as did the index of endothelial function determined by RH-PAT. 
Patients implanted with an LVAD for long periods often develop serious hemorrhage in the 
cerebrum or elsewhere, as well as drive-line infection. We were concerned that the therapy 
would aggravate hemorrhage or infection in patients through its vasodilatory effects. 
However, we found that oozing of blood at the insertion site of the LVAD drive-line tended 
to resolve during therapy. Sauna thermal therapy attenuates psychological stress (Kihara et 
al., 2004). Because of a donor shortage in Japan, patients must remain attached to an LVAD 
www.intechopen.com
 Ventricular Assist Devices 
 
132 
and stay in hospital for over 2 years while waiting for a heart transplant (Takatani et al., 
2005). The decrease in plasma norepinephrine indicated that appendicular thermal therapy 
also might attenuate psychological, as well as physical stress. 
Compared to pharmacological vasodilator therapy and other non-pharmacological therapy, 
such as cardiac resynchronization therapy and physical therapy, lower limb thermal therapy 
for CHF has several advantages. First, it is quite safe and has no adverse effects. Second, it is 
less expensive and more cost-effective. Third, unlike physical therapy, 
patients who are elderly or who have severe congestive heart failure, uncontrolled 
ventricular arrhythmias, and orthopedic limitations are not excluded from undergoing 
lower limb thermal therapy. Fourth, this treatment promotes mental and physical 
relaxation. Lower limb thermal therapy may thus be a valuable adjunct to pharmacological 
or non-pharmacological intervention in the management of CHF.  
5. Study limitation 
Although the present study is preliminary one, sample size was only five patients.  
Recruitment of study subjects is still ongoing. In the present protocol, the study subjects 
were implanted with LVAD for end-stage heart failure, and were therefore unlike typical 
patients with CHF.  
6. Conclusion 
Although the study used a very small cohort, I confirmed that lower limb thermal therapy 
was quite safe and that it improved clinical symptoms and cardiac function in patients with 
extracorporeal LVAD who were awaiting heart transplantation. The procedure of lower 
limb thermal therapy might benefit other patients, including those with end-stage heart 
failure. 
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